Patient preference, efficacy, and compliance with zoledronic acid for glucocorticoid-induced osteoporosis in patients with autoimmune diseases.

Ji-Won KimJu-Yang JungHyoun-Ah KimHeejun SonChang-Hee Suh

Published in: Postgraduate medical journal (2024)

Patients showed a preference for and greater satisfaction with zoledronic acid, and its efficacy in treating osteoporosis was comparable to that of oral BPs. Therefore, zoledronic acid is a suitable treatment option for GIOP in patients with autoimmune diseases.

Keyphrases

postmenopausal women
end stage renal disease
bone mineral density
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
case report
peritoneal dialysis
high glucose
patient reported outcomes
body composition
combination therapy